Ventana Preparing HPV Test Submission, Will Co-Market With ChromaVision
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical Systems plans to seek premarket approval for its Inform human papilloma virus (HPV) test by year-end as a follow-up screen for women whose Pap results show atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intra-epithelial lesions (LSIL)